Compare CORT & EAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CORT | EAT |
|---|---|---|
| Founded | 1998 | 1975 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 9.5B |
| IPO Year | 2001 | 1994 |
| Metric | CORT | EAT |
|---|---|---|
| Price | $114.23 | $237.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 21 |
| Target Price | $96.50 | ★ $183.00 |
| AVG Volume (30 Days) | ★ 1.2M | 1.2M |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 144.71 |
| EPS | 0.09 | ★ 7.90 |
| Revenue | $761,407,000.00 | ★ $5,384,200,000.00 |
| Revenue This Year | $26.08 | $9.00 |
| Revenue Next Year | $26.98 | $5.49 |
| P/E Ratio | $1,228.89 | ★ $30.19 |
| Revenue Growth | 12.79 | ★ 21.95 |
| 52 Week Low | $28.66 | $100.30 |
| 52 Week High | $122.21 | $253.71 |
| Indicator | CORT | EAT |
|---|---|---|
| Relative Strength Index (RSI) | 64.64 | 68.42 |
| Support Level | $76.41 | $132.28 |
| Resistance Level | $122.21 | N/A |
| Average True Range (ATR) | 5.13 | 10.14 |
| MACD | -0.09 | 1.35 |
| Stochastic Oscillator | 75.23 | 71.91 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Brinker International Inc operates casual dining restaurants under the brand's Chili Grill and Bar (Chili's) and Maggiano's Little Italy (Maggiano's). Chili's falls in the Bar and Grill category of casual dining. Its menu features Fresh Mex and Fresh Tex favorites including signature items such as slow-smoked baby back ribs, craft burgers, fajitas, and bottomless chips and salsa paired with tableside guacamole. Maggiano's is an Italian restaurant brand with a full lunch and dinner menu offering chef-prepared, such as appetizers, chicken, seafood, veal and prime steaks, and desserts. The company generates maximum revenue from Chili's segment.